fingolimod hydrochloride has been researched along with Lymphoproliferative Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akashi, H; Ando, K; Furuya, D; Kawada, H; Kawai, H; Kawakami, S; Matsushita, H; Moriuchi, M; Nakamura, N; Ogawa, Y; Suzuki, R | 1 |
| Don, AS; Martinez-Lamenca, C; Proia, RL; Roberts, E; Rosen, H; Webb, WR | 1 |
1 review(s) available for fingolimod hydrochloride and Lymphoproliferative Disorders
| Article | Year |
|---|---|
Peripheral T-cell lymphomas as fingolimod-associated lymphoproliferative disorder for patients with multiple sclerosis - case report with literature review.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Multiple Sclerosis | 2020 |
1 other study(ies) available for fingolimod hydrochloride and Lymphoproliferative Disorders
| Article | Year |
|---|---|
Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues.
Topics: Animals; Apoptosis; Autoimmune Diseases; bcl-2-Associated X Protein; Calcium Signaling; Caspases; Cell Membrane Permeability; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Fingolimod Hydrochloride; HeLa Cells; Humans; Immunosuppressive Agents; Jurkat Cells; Lymphoproliferative Disorders; Mice; Mice, Knockout; Mitochondria; Mutagenesis; Organ Specificity; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Protein Transport; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine; Spleen; Thymus Gland | 2007 |